Jinhui Liu

Changsha, 410008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.

Tro-score, a trogocytosis-related transcriptomic signature, identifies CD109 as a therapeutic target for reversing immunosuppression in bladder cancer.

Journal: International immunopharmacology

Published: June 20, 2026

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.

The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.

Journal: International immunopharmacology

Published: September 20, 2025

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Overcoming immunotherapy resistance in bladder cancer with a novel antibody-drug conjugate RC48.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2025

Deciphering the circadian rhythm in colorectal cancer: a bibliometric analysis of research landscape and trends.

Deciphering the circadian rhythm in colorectal cancer: a bibliometric analysis of research landscape and trends.

Journal: Frontiers in oncology

Published: March 10, 2025

Microsurgical varicocelectomy and revascularization: a novel approach to varicocele treatment.

Microsurgical varicocelectomy and revascularization: a novel approach to varicocele treatment.

Journal: Current problems in surgery

Published: February 10, 2025

Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.

Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.

Journal: BMC cancer

Published: December 30, 2024

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.

Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.

Journal: Journal of hematology & oncology

Published: September 27, 2024

Advances in research on the relationship between mitochondrial function and colorectal cancer: a bibliometric study from 2013 to 2023.

Advances in research on the relationship between mitochondrial function and colorectal cancer: a bibliometric study from 2013 to 2023.

Journal: Frontiers in immunology

Published: August 14, 2024

Insights into the historical trajectory and research trends of immune checkpoint blockade in colorectal cancer: visualization and bibliometric analysis.

Insights into the historical trajectory and research trends of immune checkpoint blockade in colorectal cancer: visualization and bibliometric analysis.

Journal: Frontiers in immunology

Published: August 10, 2024

Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer.

Oncogenic ACSM6 impairs CD8+ T cell-based immune response in bladder cancer.

Journal: Biomarker research

Published: July 22, 2024

Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.

Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis.

Journal: Cell death and differentiation

Published: July 22, 2024

Jianpi Jiedu decoction suppresses colorectal cancer growth by inhibiting M2 polarization of TAMs through the tryptophan metabolism-AhR pathway.

Jianpi Jiedu decoction suppresses colorectal cancer growth by inhibiting M2 polarization of TAMs through the tryptophan metabolism-AhR pathway.

Journal: International immunopharmacology

Published: May 08, 2024

Showing 1-12 of 27

Last Updated: 09/26/2026